OpenEvidence Gives Clinicians Free Access Intelligence Suite

OpenEvidence launched Access Intelligence on November 11, 2026, a suite of affordability and coverage tools built directly into its clinical AI platform and available immediately at no charge to all clinicians. The suite covers availability and eligibility information for more than 2,500 patient-support programs, and it arrives with a track record already attached: clinicians had written more than 500,000 prior-authorization documents on the platform before this launch.

The release targets a specific, unglamorous bottleneck in American medicine. A physician may select the correct treatment and still fail to get it to the patient, because the process of determining affordability and insurance coverage is fragmented across thousands of sources, payers and formats. Each carries its own forms, criteria and paperwork. OpenEvidence says clinicians are often left to handle that complexity during the few minutes available with a patient — or not at all.

Ania Bilski, MD, OpenEvidence's VP of Clinical AI, framed the company's goal plainly: "Choosing the right treatment should be the hard part. Getting the patient access to it shouldn't be."

What does Access Intelligence actually do?

The suite addresses the work that comes after the treatment decision. Its three functional pillars are support program discovery, enrollment, and prior-authorization drafting — tasks that currently live in phone calls, payer portals and paper forms.

Specifically, the tools cover:

• Program discovery and eligibility. Clinicians can query availability and patient eligibility for copay savings, patient assistance and insurance support services inside the platform. Program information is updated daily, according to the company.
• Enrollment. For programs requiring both clinician and patient enrollment, clinicians can download prepopulated enrollment forms or complete enrollment directly on OpenEvidence.
• Savings distribution. Clinicians can send copay savings and discount offers to patients through Patient TakeHome.
• Prior-authorization drafting. The platform generates prior-authorization requests, appeal letters and letters of medical necessity, grounded in available clinical guidelines and best practices, and can attach prior-authorization checklists and relevant ICD-10 codes.

The direct-enrollment option is the notable operational shift. The platform now handles both the search for assistance and part of the paperwork required to secure it — not merely the lookup.

In plain words: the suite collapses search, enrollment and authorization paperwork into one environment clinicians already use.

What is Patient TakeHome, and who controls it?

Patient TakeHome is the distribution channel for the savings offers, but it predates this launch. OpenEvidence introduced Patient Take-Homes on August 19, 2026 as an optional way for physicians to turn selected answers into patient educational handouts. Patients receive a secure email link and can share the curated material with family members or caregivers.

The design keeps physicians in charge. Patients cannot ask their own questions through TakeHome, and physicians retain control over what is shared and whether to share anything at all. That asymmetry matters in a period when regulators and health systems are scrutinizing how AI tools interact with patients directly. OpenEvidence has chosen a physician-mediated model rather than a patient-facing chatbot.

The takeaway: distribution of offers and educational material runs through the doctor, not around them.

How does prior-authorization drafting work here?

Prior authorization — the process by which insurers require justification before approving a treatment — is among the most-cited sources of clinician burnout and treatment delay. OpenEvidence reports the 500,000-document milestone as evidence that its drafting tools already carry real workload.

Access Intelligence grounds generated requests, appeal letters and letters of medical necessity in available clinical guidelines and best practices. Generated materials can include prior-authorization checklists and relevant ICD-10 codes, the diagnostic classification system used for billing and insurance claims.

Clinicians can edit generated letters directly in OpenEvidence. On the platform's Sackett and Snow models — the company's named AI models for clinical reasoning and document work — they can work through letters interactively, using follow-up questions to surface details reviewers look for. The workflow therefore extends beyond producing an initial draft: clinicians refine wording and build supporting material in the same platform.

The interactive-editing detail deserves attention, because a prior-authorization letter is only as good as its fit with a specific payer's criteria. Whether Sackett and Snow reliably surface what each reviewer wants, across thousands of payer-specific requirements, is exactly the claim the company's daily-updated program data must support over time.

In plain words: the tool drafts the letter, codes it, and lets clinicians interrogate and revise it before submission.

Why does consolidation of these tasks matter?

The stakes are administrative, not diagnostic — and that is the point. OpenEvidence positions Access Intelligence as the layer that sits beside the clinical evidence its platform already provides for choosing treatment. Affordability and coverage tasks now appear in the same environment as the evidence base, rather than in a separate maze of payer websites and PDF forms.

The market context gives the move weight. Prior authorization and benefits verification consume substantial clinician and staff hours, and delays between a treatment decision and patient access can stretch clinical timelines even when the clinical judgment is sound. A 2,500-program eligibility database, daily refresh, prepopulated enrollment and guideline-grounded authorization drafting address each step of that gap in sequence.

But the company's own framing leaves the measurement open. OpenEvidence says the open question is whether bringing program discovery, savings distribution, enrollment and iterative authorization drafting into one environment will reduce the administrative delays that persist after the clinical decision has been made. That is a fair statement of the uncertainty: no outcome data, approval-rate improvements or time-saved figures accompany the launch.

The free price tag also raises the standard strategic question the announcement does not address: how the capability factors into OpenEvidence's commercial model for the health systems and clinicians that license its platform. Free at launch does not establish free indefinitely, and nothing in the announcement commits to a timeline.

In plain words: the suite removes friction at every post-decision step, but its real-world effect on access delays is not yet demonstrated.

What comes next?

The November 11 launch puts the burden of proof on deployment. Clinicians already writing prior-authorizations on OpenEvidence — more than half a million documents so far — now have program discovery, enrollment and savings distribution one click away from the evidence they used to choose treatment. Whether daily-updated eligibility data and interactive letter drafting translate into measurably faster patient access, rather than merely tidier paperwork, is the metric to watch.